Navigation Links
Sequella Receives American Recovery and Reinvestment Funding Through the NIH
Date:10/5/2009

ROCKVILLE, Md., Oct. 5 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $694,000 grant supplement as part of the American Recovery and Reinvestment Act (ARRA) of 2009. The ARRA funds, issued through the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH), will assist Sequella to complete the manufacture of its lead drug candidate, SQ109, and provide drug supplies to continue NIH grant-funded research on SQ109 mechanism of action.

SQ109 is a new small molecule drug that is currently under US IND for the treatment of tuberculosis and is completing its Phase I safety studies in humans. Single, oral doses of 5 to 300 mg SQ109 were safe and well-tolerated in normal, healthy adults in a phase 1A study. In collaboration with NIAID, the Phase 1B clinical study to evaluate safety and pharmacokinetics of SQ109 administered daily for 2 weeks began in May 2009.

"We are pleased to receive these ARRA funds," said Dr. Carol Nacy, CEO of Sequella. "The ARRA funds will contribute to SQ109 manufacture by subcontractors in four different states impacted by the current economic downturn. We are extremely appreciative of continued support from the NIH and of the Federal Government for providing ARRA funding opportunities."

This supplemental ARRA funding will be used to complete process development and finalize manufacture of SQ109 active pharmaceutical ingredient.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases of epidemic potential. The company leverages its global influence, R&D platforms, and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercializa
'/>"/>

SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
2. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. CryoCor Receives FDA Approval for Right Atrial Flutter
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
11. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , August 20, 2014 Phase ... in the US  KalVista Pharmaceuticals ("KalVista"), an ... (DME), today announces that it has begun a Phase ... kallikrein inhibitor, KVD001, for the treatment of DME. The ... the Beetham Eye Institute, Joslin Diabetes Center; Harvard Medical ...
(Date:8/19/2014)... , Aug. 19, 2014   Lincor ... its patient experience technology to New ... the five-year agreement, CarePoint Health will deploy Lincor,s ... Medical Center, Christ Hospital and Hoboken University Medical ... a range of software solutions to help hospitals ...
(Date:8/19/2014)... -- The Alabama Supreme Court, in a 6-3 decision on August ... mislead doctors into believing that prescription medicines the companies market ... Wyeth, and the decision came after the Supreme Court ruled ... Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a clear ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4
... 13 Octapharma USA ... therapy development specifically for von Willebrand Disease (VWD), is now ... Food and Drug Administration (FDA) has approved wilate® ... in patients with severe VWD as well as in patients ...
... May 13 Stereotaxis, (Nasdaq: STXS ... with complex arrhythmias such as atrial fibrillation, ventricular tachycardia, ... the scientific program of the 31st Annual Heart Rhythm ... presentations and eight posters will underscore the broad clinical ...
Cached Medicine Technology:Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease 4New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 2New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 3New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 4New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 5New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 6
(Date:8/20/2014)... No matter how “lonely” a person may be, he ... friends to be always there for them. However, it is ... making new friends during adulthood : not only is ... of one’s family to a near-slavish devotion to career-building, the ... just is not the same as it was when one ...
(Date:8/20/2014)... 20, 2014 Building on growing ... successfully predicted stage iii and iv pressure ulcers ... situations, approached 90%. A company spokesperson commented that ... commercial or academic settings. The resulting capabilities can ... of hospital-acquired conditions to help providers avoid financial ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 “Have you recently ... auto accident and personal injury lawyer serving the greater Seattle ... incident? If so, then keep reading . , In ... individuals injured in an auto accident can use to see ... explains that a personal injury insurance claim will allow an ...
(Date:8/20/2014)... Ticketability.com has Theresa Caputo ... prices. The well-known medium has been thrilling many with ... in 19 cities, with tickets becoming available August 15. ... visit are Albany, Baltimore, Trenton, Erie, Buffalo, Philadelphia, Charlotte, ... and San Diego. The medium’s fans can obtain Theresa ...
(Date:8/20/2014)... Wisconsin (PRWEB) August 20, 2014 BuyCheapTicketsToEvents.com ... and a wide selection of tickets to many events. Cheap ... that will begin in September. , Hockey fans are enthusiastic ... to obtain tickets for games. Now is the time to ... to begin in mere months. There will be a great ...
Breaking Medicine News(10 mins):Health News:‘How to Make Friends as an Adult by Just Being Yourself: Becoming a “People Person” In Three Steps or Less’ Gives Tips for Making Friends During Adulthood - Vinamy 2Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2
... pediatric research institution , ... Washington, DC (Vocus) November ... Research Institute , dedicated new research facilities today, increasing the space ... than 100,000 square feet. , , , , ,Elected officials and ...
... MedNotes offers personalized medication profiles, drug interaction and warning ... , NEW YORK, Nov. 24 ... medication and related health issues, today announced the launch ... way consumers can monitor and manage their own medications, ...
... For over a decade Ochsner Health System,has enjoyed a ... improved patient care, cost savings and increased revenues for,Ochsner,s ... New Orleans have,seen more than their share of tragedy. ... left the greater New Orleans hospital infrastructure,badly damaged. ...
... With the bWell-informed Health Plan Forecaster, Medicare shoppers can ... , NEW YORK, Nov. ... first day of the holiday shopping rush. For seniors ... options, there,s no better time to "shop" for coverage ...
... Nov. 24 In preparation for its January 1,2009 ... Francisco,s highly regarded Institute on Aging (IOA). , ... nonprofit, membership-based, "aging-in-place",program designed to help older adults and ... apartments, and neighborhoods as long as they wish or ...
... 75th Annual Stockholders Meeting of Florida’s Natural Growers ... on Monday, the 17th of November. The theme ... Value,” was appropriate since the Cooperative reported one ... despite an extremely challenging economic environment. In fact, ...
Cached Medicine News:Health News:Children's National Dedicates New Research Facility 2Health News:Children's National Dedicates New Research Facility 3Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 2Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 3Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 4Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 5Health News:Ochsner Health System, Surgical Information Systems Partner to Rebuild New Orleans Healthcare Infrastructure 2Health News:Ochsner Health System, Surgical Information Systems Partner to Rebuild New Orleans Healthcare Infrastructure 3Health News:bWell-informed(TM) Adds Medicare Plan Tools for 2008 Open Enrollment Season 2Health News:Institute on Aging Collaborates With New Program San Francisco Village 2Health News: Florida's Natural Celebrates 75 Years with Record Performance 2Health News: Florida's Natural Celebrates 75 Years with Record Performance 3
... Cruise Control is ... STAAR as a filter ... and aspiration tubing that ... the safety and efficiency ...
... The robust, compact Sleepscan Traveler provides the ... can acquire PSG data in the home, ... laboratory. Traveler sleep studies utilize the same ... in-lab studies. Sleepscan Traveler studies take full ...
... Pioneer in Digital EEG ,The company ... system presents the latest addition to ... VISION. This innovative system incorporates the ... and information management to offer you ...
"Ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Complies with international standards of electrophysiology....
Medicine Products: